SUBSEQUENT EVENTS	12 Months Ended
Dec. 31, 2019
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 21 SUBSEQUENT EVENTS In accordance with ASC Topic 855, “Subsequent Events”, the Company evaluated subsequent events through April 9, 2020, the date these financial statements were available to be issued. During their evaluation, the following subsequent events were identified. Issuance of debt and warrants Subsequent to the balance sheet date, the Company has issued $182,000 of promissory notes. All of the debt matures in 2021 and has a stated interest rate of 12% and is unsecured. Concurrent with the issuance of debt, the Company has issued 3,114,000 warrants at an average exercise price of $0.21. At the time of issuance, all warrants had a three or five year term. Issuance of common stock The Company has not issued any shares subsequent to December 31, 2019. Coronavirus Outbreak In early 2020, an outbreak of a novel strain of coronavirus was identified and infections have been found in a number of countries around the world, including the United States. The coronavirus and its impact on trade including customer demand, travel, employee productivity, supply chain, and other economic activities has had, and may continue to have, a significant effect on financial markets and business activity. The extent of the impact of the coronavirus on our operational and financial performance is currently uncertain and cannot be predicted.

SUBSEQUENT EVENTS

12 Months Ended

Dec. 31, 2019

NOTE 21 SUBSEQUENT EVENTS

In accordance with ASC Topic 855, “Subsequent Events”, the Company evaluated subsequent events through April 9, 2020, the date these financial statements were available to be issued. During their evaluation, the following subsequent events were identified.

Issuance of debt and warrants

Subsequent to the balance sheet date, the Company has issued $182,000 of promissory notes. All of the debt matures in 2021 and has a stated interest rate of 12% and is unsecured. Concurrent with the issuance of debt, the Company has issued 3,114,000 warrants at an average exercise price of $0.21. At the time of issuance, all warrants had a three or five year term.

Issuance of common stock

The Company has not issued any shares subsequent to December 31, 2019.

Coronavirus Outbreak

In early 2020, an outbreak of a novel strain of coronavirus was identified and infections have been found in a number of countries around the world, including the United States. The coronavirus and its impact on trade including customer demand, travel, employee productivity, supply chain, and other economic activities has had, and may continue to have, a significant effect on financial markets and business activity. The extent of the impact of the coronavirus on our operational and financial performance is currently uncertain and cannot be predicted.